Navigation Links
Optimer Reports First Quarter 2013 Financial Results
Date:5/9/2013

rease was due to an increase in DIFICID net product sales and an increase in contract revenue.

DIFICID net product sales in the United States and Canada for the quarters ended March 31, 2013 and 2012 were $16.8 million and $14.4 million, respectively, an increase of $2.4 million.  This increase was due to an increase in the number of customers ordering DIFICID and increased sales to existing DIFICID customers, as well as the impact of a 5.6% price increase effective January 3, 2013.  We recognize product sales of DIFICID upon delivery of product to our wholesalers.

Contract revenue for the quarter ended March 31, 2013 was $2.6 million.  There was no contract revenue in the quarter ended March 31, 2012.  The $2.6 million was related to fidaxomicin shipments to Astellas Pharma Europe, Astellas Japan, AstraZeneca and Specialised Therapeutics Australia, as well as royalties received from Astellas Pharma Europe.  In addition, we recognized approximately $0.3 million of revenue on the up-front payments we received from AstraZeneca and Astellas Japan in the prior year.

Cost of product sales for the three months ended March 31, 2013 and 2012 was $1.6 million and $1.2 million, respectively.  The increase was due to higher net product sales in the quarter ended March 31, 2013 as compared to the year-ago period.

Research and development expense for the quarters ended March 31, 2013 and 2012 was $9.9 million and $11.1 million, respectively, a decrease of $1.2 million. The decrease was primarily due to lower chemistry, manufacturing and control (or CMC) expenses, as well as lower consulting expenses. The decrease was offset by higher health economics and outcomes research expenses. We also incurred higher expenses related to our prophylaxis and pediatric clinical trials.

Selling, general and administrative expense for quarters ended March 31, 2013 and 2012 w
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
2. Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
3. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
4. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
5. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
6. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
7. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
10. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
11. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- Emergency ... design, blended emergency medical training and response technologies, ... defibrillator) training from the Department of Homeland ... Reserve 81 st Regional Support Command ... contract includes nationwide CPR/AED/First Aid training. The Army ...
(Date:8/27/2014)... , Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that certain members of the ... Healthcare Conference to be held September 8-10, 2014 in ... , Chief Executive Officer and President, is scheduled to ... portfolio at 10:55 a.m. ET on Wednesday, September 10, ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... The American Brain Tumor Association is ... Research Fellowships and 2014-2015 Discovery Grant Awards. Through the ... the field with talented, bright young investigators who have ... effects, diagnosis and treatment of brain tumors. This year’s ... the potential to advance the understanding and treatment of ...
(Date:8/27/2014)... Albany, New York (PRWEB) August 27, 2014 ... published by Transparency Market Research "Ablation Technologies Market ... Technologies: Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - ... Forecast, 2014 - 2020," the global ablation technologies ... 2013 and is estimated to reach a market ...
(Date:8/27/2014)... Center for Leadership in Disability (CLD) has received ... Child Health Bureau of the Health Resources and ... Plan for Georgia, aimed at improving services for ... In preparing for this project, CLD worked with ... from across Georgia. The resulting plan addresses priorities ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5
... in the last one month in Deomali and its ... officer N Singh said today. // ,Singh ... war footing to bring the situation under control., ... claimed death of 20 people in 15 days and ...
... of Georgia say that even if the surgery has gone ... of cardiovascular disease// and possibly cancer for several weeks post-operatively. ... is that when bad things happen down the road, months, ... in the past, just attribute it to the natural course ...
... today said it has entered into an agreement with ... of Foot and Mouth Disease (FMD) vaccine developed by ... the agreement, we will produce and market the vaccine ... meet the requirements of the domestic market and if ...
... 6. Even as asthma patients from different parts of ... fish medicine, rationalists have stepped up their campaign against ... of rationalists, has again urged the Andhra Pradesh government ... 'drug' was based on 'superstition'. ,The Bathini family, ...
... activity of a protein called NFATc1 tends to cause ... treat osteoporosis //- HHMI investigator Gerald Crabtree and HHMI ... bone is constantly being formed and being broken down ... cells called osteoblasts replenish it. ,‘Ideally, ...
... illness, which was under-diagnosed till now was found to ... thought before//. Intermittent Explosive Disorder or Rage disorder is ... outbursts. This illness if left untreated may also lead ... ,Intermittent Explosive Disorder attacks are out of proportion to ...
Cached Medicine News:Health News:Well-Planned Surgeries Also Carry Health Risks 2Health News:Well-Planned Surgeries Also Carry Health Risks 3Health News:'Fishy' Medicine Stirs Controversy 2Health News:'Fishy' Medicine Stirs Controversy 3Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 2Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 3
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: